Ensartinib (X-396) Effectively Modulates Pharmacokinetic Resistance Mediated by ABCB1 and ABCG2 Drug Efflux Transporters and CYP3A4 Biotransformation Enzyme

Ensartinib (X-396) Effectively Modulates Pharmacokinetic Resistance Mediated by ABCB1 and ABCG2 Drug Efflux Transporters and CYP3A4 Biotransformation Enzyme

Ensartinib (X-396) is a promising tyrosine kinase inhibitor currently undergoing advanced clinical evaluation for the treatment of non-small cell lung cancer. In this work, we investigate possible interactions of this promising drug candidate with ATP-binding cassette (ABC) drug efflux transporters...

Full description

Bibliographic Details
Main Authors: Dimitrios Vagiannis, Eva Novotna, Adam Skarka, Sarah Kammerer, Jan-Heiner Küpper, Si Chen, Lei Guo, Frantisek Staud, Jakub Hofman
Format: Article
Language:English
Published: MDPI AG 2020-03-01
Series:Cancers
Subjects:
ensartinib
cancer
multidrug resistance
drug-drug interaction
ABC transporter
cytochrome P450
Online Access:https://www.mdpi.com/2072-6694/12/4/813

Internet

https://www.mdpi.com/2072-6694/12/4/813

Similar Items